CCI Closes Section 4 Case Against St. Stephen's Hospital Delhi, Rejects DG's Aftermarket Abuse Findings
The Competition Commission found the Director General's methodology flawed on room rent, diagnostics, consumables and medicines, and declined to delineate a separate aftermarket for admitted patients.
The Competition Commission of India has closed Case No. 77(12) of 2015 against St. Stephen's Hospital, Delhi, finding no contravention of Section 4 of the Competition Act, 2002. The order, passed on 21 May 2026 by a four-member bench led by Chairperson Ms. Ravneet Kaur, rejected the Director General's supplementary investigation report which had concluded that the hospital abused its dominant position by charging excessive prices for room rent, medical tests, medical devices, consumables, and medicines to admitted patients. The Commission found the DG's market delineation methodology flawed, declined to treat the hospital's in-patient services as a separate aftermarket, and held that neither of the two tests for unfair pricing established in United Brands was satisfied on any count. All pending interlocutory applications stand disposed of.
How a Syringe Complaint Became a Twelve-Hospital Inquiry
The case began in 2015 when informant Shri Vivek Sharma filed information under Section 19(1)(a) of the Act against Becton Dickinson India (P) Ltd. and Max Super Specialty Hospital, Patparganj, Delhi. The allegation was that Becton Dickinson, a manufacturer of disposable syringes, colluded with Max Patparganj to print a higher Maximum Retail Price on syringes sold at the hospital's in-house pharmacy compared to the same product sold in the open market.
The Commission formed a prima facie view of contravention of Section 4 and directed the Director General to investigate under Section 26(1) on 17 November 2015. The DG's main investigation report found no collusion between Becton Dickinson and Max Patparganj under Section 3(3), and the Commission confirmed that finding in its order dated 31 August 2018. However, the Commission noted that the DG had flagged Max Patparganj's conduct as potentially amounting to aftermarket abuse but had not analysed it in sufficient depth. The Commission directed a supplementary investigation, broadening the scope to all aftermarket healthcare products and services provided by super-specialty hospitals in Delhi to their admitted patients.
The DG's supplementary investigation report, submitted in confidential version on 24 December 2021, covered twelve super-specialty hospitals in Delhi. On 11 January 2022, the Commission deleted Becton Dickinson from the array of opposite parties and impleaded the eleven additional hospitals alongside Max Patparganj. The Commission directed that the matter be treated as twelve separate sub-cases, with independent reports and separate hearings for each hospital. After further procedural steps—including the preparation of unredacted reports submitted on 18 September 2024—hearings on the supplementary report and penalty quantum took place on 28 August, 2 September, 29 October, and 30 October 2025. The present order relates to sub-case No. 77(12) of 2015, assigned to St. Stephen's Hospital, Delhi.
What the DG Found Against St. Stephen's Hospital
The DG's supplementary report framed five issues. On enterprise status, the DG found all twelve hospitals to be enterprises under Section 2(h) of the Act, given their commercial activity of providing medical services for monetary consideration. On relevant market, the DG defined twelve separate markets—one per hospital—as the “market for provision of healthcare services/ facilities for in-patients admitted to the respective private super specialty hospital” with Delhi as the geographic market. Each hospital was found dominant in its own market on the basis that no other hospital exercised influence over its management or policies.
On the question of abuse, the DG concluded that all twelve hospitals contravened Section 4 between 2015 and 2018 across five parameters. On room rent, the DG found that all twelve hospitals charged more than nearby three-star and four-star hotels and other nearby hospitals. On medical tests, the DG compared prices for thirteen routine tests against four diagnostic laboratories and found that each hospital charged more for one or more tests at some point during the period. On medical devices, the DG analysed prices for bare metal stents, biodegradable stents, knee implants, and hip implants, noting an increasing price trend. On consumables and medicines, the DG compared procurement prices against selling prices and found significant profit margins across all twelve hospitals.
Notably, the DG's own report recorded that St. Stephen's Hospital was the only one among the twelve that did not require patients to procure medicines from its in-house pharmacy. Four pharmacies and chemist shops operated in close proximity to the hospital's premises.
St. Stephen's Hospital: The Case Against the DG's Approach
St. Stephen's Hospital, represented by Ms. Shruti Sharma, Ms. Shreya Sharma, and Mr. Nishant Kandpal, Advocates, challenged the DG's findings on multiple grounds.
The hospital argued that the relevant market had been incorrectly defined around a single hospital, ignoring competitive alternatives across Delhi-NCR. It contended that patients and their families choose a hospital based on price, reputation, facilities, packages, and accessibility—and that this choice is exercised before admission. Competition among hospitals therefore operates at the pre-admission stage and is not eliminated by the fact that a hospital provides integrated services once a patient is admitted.
On the specific finding that it compelled patients to buy from its pharmacy, the hospital pointed out that the DG's own report acknowledged it was the only hospital that did not impose such a requirement. The presence of four nearby pharmacies operating commercially near its premises was cited as evidence that patients could and did procure medicines from outside.
On pricing methodology, the hospital argued that comparing hospital room tariffs with hotel rates mischaracterised healthcare as a leisure service, ignoring clinical responsibilities and infrastructure costs. On consumables and medicines, it submitted that selling at MRP is legally permissible and that no law obliges a hospital to pass on procurement margins to patients.
The Commission's Reasoning on Relevant Market
The Commission's analysis turned first on whether a separate aftermarket exists for in-patients, distinct from the primary market for hospital healthcare services.
The Commission identified three conditions relevant to aftermarket delineation: whether consumers engage in whole-life costing; whether reputation effects deter the provider from setting competitive prices in the secondary product; and whether switching costs in the primary market are substantial enough to lock consumers in.
On whole-life costing, the Commission found that patients seeking elective treatment are typically given an estimated cost before admission that covers the procedure, drugs, consumables, room rent, and related services. Patients retain the freedom to accept or reject the estimate, seek a second opinion, or choose another hospital. The Commission acknowledged that the final cost may vary from the estimate due to complications, additional diagnostics, or extended stays, and that the estimate does not give granular per-consumable pricing. However, it concluded that patients have a reasonable degree of information to undertake a comparative analysis of total treatment costs before admission.
On reputation effects, the Commission accepted that for well-established hospitals, factors such as high demand, brand image, and the availability of renowned doctors may mean that the risk of losing market share in the primary market does not effectively constrain pricing in secondary services such as in-house diagnostics, medicines, and consumables.
On switching costs, the Commission acknowledged that procedural barriers to discharge—process delays, waivers, information asymmetry, health risks in transition, and the routine insistence by receiving hospitals on fresh diagnostic tests—may impose some costs on patients wishing to switch. However, it found that patients are free to leave at any time and that, by and large, sufficient flexibility exists to exercise choice at various stages of treatment.
Weighing these factors together, and in the absence of evidence that patients cannot ascertain the lifetime cost of treatment or cannot switch without incurring substantial switching costs, the Commission declined to delineate separate primary and secondary (aftermarket) markets. It adopted a unified relevant product market for in-patients admitted for elective treatment.
Why the DG's Abuse Findings Did Not Survive Scrutiny
Having defined the relevant market differently from the DG, the Commission then examined each of the five parameters on which abuse had been alleged.
On room rent, the Commission found that comparing hospital room tariffs with hotel rates was an inappropriate benchmark. Hospitals provide round-the-clock clinical care, nursing, monitoring, and medical infrastructure that hotels do not. The Commission held that the DG's comparison was not a valid basis for a finding of unfair pricing.
On medical tests, the Commission found that the DG's comparison of hospital test prices with standalone diagnostic laboratories did not account for the higher operational costs of a hospital-based testing facility, which must maintain twenty-four-hour availability, staffing, and faster turnaround times. The Commission also found that the comparison was made against only one standalone laboratory for X-ray, MRI, and ultrasound procedures, which it considered inadequate. It held that charges would qualify as unfair only where they are significantly higher than those charged by other hospitals for comparable services—a comparison the DG did not make.
On medical devices, the Commission similarly found the DG's finding unsustainable, noting that the analysis relied on isolated instances of higher pricing without adequate comparative benchmarks from other hospitals.
On consumables and medicines, the Commission found that comparing procurement prices with selling prices to derive a profit margin was not an appropriate methodology, because procurement prices do not capture overhead expenses including storage, supply chain management, operational costs, and inventory management. The Commission also noted that there was no finding in the supplementary report that the hospital had charged beyond the MRP fixed by the manufacturer for any product. It further observed that no law obliges a hospital to pass on procurement margins to patients. The sample size of consumables and medicines examined by the DG was described as quite limited.
Across all parameters, the Commission concluded that neither of the two tests for establishing unfair pricing under the United Brands framework had been satisfied on any count.
Regulatory Context the Commission Placed on Record
Before reaching its findings, the Commission set out the regulatory framework governing medicine and device pricing in India. The Drugs and Cosmetics Act, 1940 governs manufacture, sale, and distribution. The Drug Price Control Order, 2013, issued under Section 3 of the Essential Commodities Act, 1955, caps prices of drugs on the National List of Essential Medicines. The National Pharmaceutical Pricing Authority oversees implementation and permits annual MRP increases of up to ten per cent for scheduled drugs. Prices of medical devices are regulated through the Medical Devices Rules, 2017.
The Commission also noted a judgment of the Supreme Court of India dated 4 March 2025 in Siddharth Dalmia and Another v. Union of India and Others (Writ Petition (C) No. 337 of 2018), in which the Apex Court examined whether the affairs of private hospitals with reference to fixation of prices of drugs and equipment sold from their pharmacies can be regulated through administrative or legislative measures. The Supreme Court observed that the issue primarily involves policy decisions and did not express any opinion on the merits.
Order
The Commission closed Case No. 77(12) of 2015 against St. Stephen's Hospital, Delhi, finding no contravention of Section 4 of the Competition Act, 2002. All pending interlocutory applications stand disposed of.
The Commission granted confidentiality to documents, data, and information filed by the hospital under Regulation 35 of the General Regulations, 2009 (as amended), in terms of Regulation 36 of the General Regulations 2024, read with Section 57 of the Act, for a period of three years from the date of the order. It was made clear that nothing disclosed in the order itself is deemed confidential.
The Secretary was directed to communicate a certified copy of the order to the opposite party.